Giancarlo Agnelli

Medicina Interna e Cardiovascolare – Stroke Unit

Scuola di Specializzazione in Medicina d'Emergenza-Urgenza Università di Perugia



- Clinical examination (I)
- ICH or ischemic stroke?
- Clinical examination (II)
- Reperfusion therapy & antithrombotic therapy
- Malignant MCA
- Management of complications
- Stroke Unit

- Clinical examination (I)
- ICH or ischemic stroke?
- Clinical examination (II)
- Reperfusion therapy & antithrombotic therapy
- Malignant MCA
- Management of complications
- Stroke Unit

Sudden onset of signs of focal or global disturbance of cerebral function * with no apparent nonvascular cause**

* lasting more than 24 h (unless interrupted by specific treatment, surgery or death)

 ** epilepsy brain tumor brain abscess encephalitis multiple sclerosis & other inflammatory diseases metabolic causes hysteria

- Clinical examination (I)
- ICH or ischemic stroke?
- Clinical examination (II)
- Reperfusion therapy & antithrombotic therapy
- Malignant MCA
- Management of complications
- Stroke Unit

Ischemic vs. hemorrhagic stroke



80-90%

10-20%

For most patients with ICH, the usefulness of surgery is uncertain (Class IIb; Level of Evidence: C)

Specific exceptions:

 Patients with cerebellar hemorrhage who are deteriorating neurologically or who have brainstem compression and/or hydrocephalus from ventricular obstruction should undergo surgical removal of the hemorrhage as soon as possible (Class I; Level of Evidence: B)

 For patients presenting with lobar clots >30 mL and within 1 cm of the surface, evacuation of supratentorial ICH by standard craniotomy might be considered (Class IIb; Level of Evidence: B)



Fighting Heart Disease and Stroke

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage American Heart Association, 2010

Management of patient with ICH



Management of patient with ICH





SEDI TIPICHE

- A: emisferica
- B: gangliare
- C: talamica
- D: pontina
- E: cerebellare

Management of patient with VKA-associated ICH

- 1. Immediate VKA withdrawal
- 2. Vitamin K
- 3. Fresh frozen plasma (PFC)
- 4. Prothrombin complex concentrates (PCC)
- 5. Recombinant FVa

- Clinical examination (I)
- ICH or ischemic stroke?
- Clinical examination (II)
- Reperfusion therapy & antithrombotic therapy
- Malignant MCA
- Management of complications
- Stroke Unit

The relevance of clinical examination (I)



Male, 84 years

Prior ischemic left hemispheric stroke (October 2011) Persistent atrial fibrillation No warfarin treatment for poor compliance

Acute worsening of right limbs weakness and speech disturbance

Neurological examination: aphasia, right hemiparesis, right gaze deviation

The relevance of clinical examination



Male, 84 years

Prior ischemic left hemispheric stroke [October 2011] Persistent atrial fibrillation No warfarin treatment for poor compliance

Acute worseninig of right limbs weakness and speech disturbance

Neurological examination: aphasia, right hemiparesis, right gaze deviation Male, 71 years with AFib on warfarin

- Dysarthria
- Severe paresis of left upper limb(1/5)
- Mild paresis of left lower limb (4/5)
- Central paresis of left VII cranial nerve
- Disturbance of superficial sentitivity in the left upper limb
- Complete paresis of horizontal coniugate gaze toward left without forced deviation

Esame obiettivo neurologico all'ingresso

- Disartria
- Paresi severa dell'arto superiore di sinistra (funzionalità residua 1/5)
- Paresi lieve arto inferiore di sinistra (funzionalità residua 4/5)
- Paresi del VII nervo cranico di sinistra a semeiologia centrale
- Deficit sensitivo (sensibilità superficiali) all'arto superiore di sinistra
- Paresi completa dei movimenti coniugati oculari orizzontali verso sinistra (senza deviazione forzata)



Ospedale R.Silvestrini PG

2mm

Male, 71 years with AFib on warfarin

- Dysarthria
- Severe paresis of left upper limb(1/5)
- Mild paresis of left lower limb (4/5)
- Central paresis of left VII cranial nerve
- Disturbance of superficial sentitivity in the left upper limb
- Complete paresis of horizontal coniugate gaze toward left without forced deviation

RM DWI: ischemia recente!!!



isoReg - DWI SENSE SCOLARE INTRACRANIGO - Diffusione - RM ence

SE:305

IM:152

10/10/2011

18:41:08

SA

SE:305

IM:136

10/10/2011

18:41:08

SA

TC-Scan: 03.01.2012



Cardioembolic



Venous



Ischemic Stroke

Unknown cause



Hemodynamic



Aterothrombotic



Small vessel disease





Many other pathologies

CAA

- Clinical examination (I)
- ICH or ischemic stroke?
- Clinical examination (II)
- Reperfusion therapy & antithrombotic therapy
- Malignant MCA
- Management of complications
- Stroke Unit

Functional changes during acute cerebral ischemia



Thrombolytic trials with rt-PA (N=2955)

Wardlaw, Cochrane Database Syst Rev 2003



NNT and NNH with rt-PA



Wardlaw, Cochrane Database Syst Rev 2003

For eligible patients, we recommend the administration of iv t-PA in a dose of 0.9 mg/Kg (maximum 90 mg), with 10% of the total dose given as an initial bolus and the remainder infused over 60 minutes, provided that treatment is initiated within 3 (4.5) hours of clearly defined symptoms

ECASS 3	
---------	--

Main results				
	rt-PA (n= 418)	Placebo (n = 403)		
m-RS (0-1)	52.4%	45.2%		
Symptomatic ICH	2.4%	0.2%		
Death	7.7%	8.4%		

Hacke et al., N Engl J Med 2008

Thrombolysis- Selection of patients

```
Age 18-80
```

- Acute focal neurological deficit (not improving)
- Stroke severity, NIH SS < 26
- Onset >30 minutes, <3 hours
- No recent stroke, trauma, surgery, GI/urinary bleeds
- No recent (<48 hours) anticoagulation
- BP <u><</u> 185/110
- Normal PT& APTT & platelets count
- Blood glucose (2.7-22.2)



Figure 2: Early CT signs in acute MCA stroke Left and middle: Hyperdense left MCA sign (yellow arrow), hypoattenuated left basal ganglia (red arrow), and cortical swelling (blue arrows) in the same patient. Right: Dot sign (yellow arrow) in the left sylvian fissure.

PWI lesion > DWI lesion

PWI lesion = DWI lesion

PWI lesion < DWI lesion



Antithrombotic Trialists' Collaboration



9 eventi vascolari ogni 1000 pazienti trattati per 3 settimane

Anticoagulation for acute stroke

Mortality and disability

Anticoagulants vs. aspirin or placebo OR (random) = 1.01 (0.82 - 1.24)

Mortality and disability Anticoagulants vs aspirin OR (random) = 1.14 (0.95 – 1.38)

Hemorragic transformation Anticoagulant vs aspirin or placebo) OR (random) = 3.76 (2.03 – 6.96)

Paciaroni et al., Stroke 2007

- Clinical examination (I)
- ICH or ischemic stroke?
- Clinical examination (II)
- Reperfusion therapy & antithrombotic therapy
- Malignant MCA
- Management of complications
- Stroke Unit







🚳 WEB1000 Studio Anteprima Visualizza Referto Conferenza 1 42 70 **>** A125 VIN Cod.esame: M132729 Сс SE: 4 IM: 42 31-lug-1960 M 24-nov-2010 6.49.13 R 1 2 5 1 2 5 W: 148, C: 30 Ospedale R.Silvestrini PG MAG: 115% DEFAULT 3.7:1 P125 ď, ID utente : 8179, Team : Unrestricted Team 10.2.1.28 00:01 Visualizza le immagini... 🛃 start IT 🔇 🏷 🧊 🗊 14.46 60 Microsoft PowerPoint ... C WEB1000 Login - Micr... WEB1000



- Clinical examination (I)
- ICH or ischemic stroke?
- Clinical examination (II)
- Reperfusion therapy & antithrombotic therapy
- Malignant MCA
- Management of complications
- Stroke Unit

In-hospital complications of acute stroke

January 1° 2010 – September 30 2011 (administrative data)

	(n=607)	%
Pneumonia	76	12.5
Urinary tract infection	51	8.4
Venous thromboembolism	50	8.2
Acute heart failure	31	5.1
Cardiac arrhythmias	28	4.6
Upper GI hemorrhage	15	2.5
Acute myocardial infarction	13	2.1
Acute limb ischemia	8	1.3

Stroke Unit University of Perugia



Segni ecografici di polmonite

- Area ipoecogena
- Di dimensione variabili
- Di forma irregolare
- A contatto con la linea pleurica
- Circondata da B lines
- Contenente broncogrammi
- Associata o meno a versamento pleurico



Cardiovascular adverse events

Acute coronary syndromes Arrhythmias Sudden death Congestive heart failure Venous thromboembolism Uncontrolled hypertension Acute arterial thromboembolism Bleeding associated with antithrombotic treatment

ECG abnormalities occur in 90% of patients

ST- segment depression T-wave inversion QT Dispersion

Consequence of acute myocardial ischemia vs. non specific ECG findings

Fure et al., J Intern Med 2007

Arrhythmias

352 ischemic and 98 hemorrhagic stroke

New onset ECG abnormalities in 75% of patients Definite arrhythmias in 28.7% of the cases

21.9% of ischemic stroke (R 26.8%*, L 14.3%)20.4% of the hemorrhagic stroke37.5% subarachnoid hemorrhage

* Cardiac control rhythm site in the MCA territory

Daniele et al., J Stroke Cerebrovasc Dis 2002

ECG abnormalities occur in 90% of patients

ST- segment depression T-wave inversion QT Dispersion

Consequence of acute myocardial ischemia vs. non specific ECG findings

Fure et al., J Intern Med 2007

Arrhythmias

352 ischemic and 98 hemorrhagic stroke

New onset ECG abnormalities in 75% of patients Definite arrhythmias in 28.7% of the cases

21.9% of ischemic stroke (R 26.8%*, L 14.3%)20.4% of the hemorrhagic stroke37.5% subarachnoid hemorrhage

* Cardiac control rhythm site in the MCA territory

Daniele et al., J Stroke Cerebrovasc Dis 2002

Stroke-induced myocardial injury

- 1. Absence of primary cardiac causes
- 2. Associated with intense sympathetic nervous system activation
- 3. Particularly common in ischemic lesions of the insula (both right and left sides)

VTE without prophylaxis in hospitalized patients

Venous thromboembolism



Geerts et al. Chest, 2004; Leizorovicz et al. Circulation. 2004

- Clinical examination (I)
- ICH or ischemic stroke?
- Clinical examination (II)
- Reperfusion therapy & antithrombotic therapy
- Malignant MCA
- Management of complications
- Stroke Unit



Organized inpatient (stroke unit) care for stroke (Cochrane review)

Stroke Units vs General Wards

N = 4911

mortality OR 0,86; IC95 0,71-0,94; P=0,005

mortality/nursing home OR 0,80; IC95 0,71-0,90; P=0,0002

dependency OR 0,78; IC95 0,68-0,89; P=0,0003

The Cochrane Library, Issue 1, 2000

Treatment options for ischemic stroke

Conclusions

	Death/dependency	Utility
Stroke Unit	0.78 (0.68 - 0.89)	Very wide
Aspirin	0.94 (0.91 - 0.98)	Wide
Thrombolysis	0.66 (0.53 - 0.83)	Narrow

Ineffective: Anticoagulation Unproven: Neuroprotection